Loading...
Founder Panel: Albert Katz (Flagler Health) and Grant Mitchell, MD (Every Cure)
Private Location (sign in to display)
3
Registered
Details
About the Startups:
Flagler Health empowers providers by leveraging the power of AI to help provide clinical and back-office support. We help physicians expand their clinical offerings and optimize patient triage, engagement, and data-gathering. Flagler Health made Poets & Quants “Most Disruptive MBA Startups of 2023” list and was a finalist in Penn’s 2023 Venture Lab Startup Challenge.
Every Cure is a nonprofit biotech organization committed to unlocking the potential of existing medicines to treat as many diseases as possible. By harnessing AI-driven platforms, rigorous preclinical and clinical testing, and global dissemination strategies, Every Cure accelerates the delivery of life-saving treatments to patients worldwide. Every Cure has been profiled on Good Morning America, USA Today, and the Wall Street Journal and selected as both an Audacious Project grantee from TED and a Founder’s Prize recipient from Elevate Prize Foundation.
About the Founders:
Albert Katz is the CEO and Co-Founder of Flagler Health. Prior to Flagler Health, Albert Katz was the Chief Financial Officer at Spine and Wellness Centers of America, a multidisciplinary musculoskeletal clinic based in Florida. Albert also previously worked at Alpine Investors, a leading private equity firm. Albert holds a BS in Business Administration from the University of Miami, a MS in Finance from Babson F.W. Olin Graduate School of Business, and a MBA from the Wharton School.
Grant Mitchell, MD, MBA, is the Co-Founder of Every Cure. He is a seasoned entrepreneur, operator and investor in the areas of health, technology, and machine learning. He has launched multiple health tech companies and operated in the CEO role in life science and tech organizations. Previously, Dr. Mitchell was a Principal in Analytics at McKinsey & Company’s artificial intelligence division, QuantumBlack. There he led teams that pioneered the use of machine learning algorithms and real world evidence databases to predict health outcomes in subpopulations by drug type. Dr. Mitchell was an integral part of the effort to support Dr. Fajgenbaum in the search for the cure of his own rare disease, and further collaborated with Dr. Fajgenbaum on the CORONA project. Every Cure is the culmination of Dr. Mitchell and Dr. Fajgenbaum’s experience in rare disease research, drug repurposing, and advanced analytics. Dr. Mitchell earned a BA in economics from New York University, MD from the University of Pennsylvania, and MBA from the Wharton School.